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Abstract
Introduction Poor adherence to anti-hypertensive treat-
ment significantly contributes to the failure to achieve well-
controlled blood pressure in patients with hypertension.
Aim To convert the original English version of Medica-
tion Adherence Self-efficacy Scale (MASES) into a Persian
version for clinical application in hypertensive patients.
Methods The backward–forward translation method was
used to produce the Persian version of the questionnaire.
Then the internal consistency was assessed using Cron-
bach’s alpha. Exploratory Factor Analysis was applied to
extract the components of the questionnaire. Correlation
between blood pressures and drug adherence was then
determined using the Persian MASES in hypertensive
patients.
Results Cronbach’s alpha coefficient of the Persian ver-
sion of MASES was [0.92, suggesting that it can yield
consistent results. Exploratory Factor Analysis suggested
an uni-dimensionality of the scale. Patients with uncon-
trolled hypertension showed poor adherence to hyperten-
sive medications, therefore had significant lower self-
efficacy scores than those with well-controlled blood
pressure by medications.
Conclusion The Persian version of MASES is valid and
reliable to assess self-efficacy of antihypertensive
medication adherence in hypertensive patient, which is
helpful to improve medication compliance in such patients
in order to achieve better blood pressure controls.
Keyword Hypertension  Blood pressure control 
Self-efficacy
1 Introduction
Hypertension is one of the major causes of cerebrovascular
and cardiovascular diseases and related mobility and
motility. Hypertension is usually a chronic asymptomatic
condition. It is estimated that worldwide about 60 % of the
adult population will develop hypertension in year 2025.
Compared to the developed countries, the risk of hyper-
tension in the developing countries has almost been dou-
bled, including Iran [1]. Uncontrolled hypertension is
defined as systolic blood pressure greater than 140 mmHg
or diastolic blood pressure greater than 90 mmHg. How-
ever, according to the latest recommendation by European
Society of Hypertension, an ideal target blood pressure is
less than 140/85 mmHg [2, 3]. In most cases, lifestyle
modification and anti-hypertensive drugs are necessary to
maintain an ideal blood pressure in order to reduce the risk
of developing cerebrovascular and cardiovascular diseases
[4].
Only a third of the patients with hypertension have
adequate control over their blood pressure levels [5]. De-
spite active and intensive drug treatment and increased
awareness, the blood pressure in hypertensive patients is
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still poorly controlled in many countries [6]. Poor adher-
ence to anti-hypertensive treatment has been shown to
significantly contribute to the failure to achieve the goals of
blood pressure management in the Seventh Report of the
Joint National Committee on Prevention, Detection,
Evaluation and Treatment of High Blood Pressure, which is
unfortunately a global phenomenon [7]. Even with the
access to effective anti-hypertensive medications, more
than half of the patients spontaneously stopped their
medication within the first year after the treatment initiated.
Moreover, among the patients who have long-term hyper-
tension, 50 % of them received more than 80 % of total
prescribed medications [8]. As a result of poor adherence to
anti-hypertensive medications, approximately 75 % of
hypertensive patients cannot achieve good control of their
blood pressure [8].
Medication-taking behavior is a complex interaction
between the biological, psychological and social factors
[9]. There are several theories to explain the adherence
behavior in hypertensive patients [10, 11]. The theory that
is well regarded is the self-efficacy theory. Self-efficacy is
defined as the perception of one’s ability to complete a
take, a goal, or a specific challenge [12]. Self-efficacy has
been considered as the most prominent predictor for health
related behavioral change, such as adherence to medica-
tions in patients with chronic diseases [9]. Hypertensive
patients with high levels of self-efficacy are more likely to
feel confident to adhere to their medications [9, 13].
Self-efficacy is a type of self-assessment and self-con-
fidence to perform a specific task, related to this study, the
adherence to anti-hypertensive medications. According to
Bandura, it is one of the most important psychological
factors that impact on medication adherence [14]. There
are increased evidence on the effects of social learning,
specifically self-efficacy, on the improvement of adherence
over the past two decades [13]. Self-efficacy has been
shown to be able to predict medication adherence in indi-
viduals diagnosed with chronic diseases [9]. McCann and
colleagues considered self-efficacy as a ‘‘cornerstone of
medication adherence’’ [15]. While there are discrepancy
in the specific types of self-efficacy for different treat-
ments, domestic specific self-efficacy is the form that im-
pacts on the treatment process and outcome [16].
Therefore, Ogedegbe and colleagues developed the
Medication Adherence Self-Efficacy Scale (MASES) to
measure and identify the situations in which patients ex-
pressed concerns about self-efficacy in adherence to pre-
scribed medications [9]. It is designed to evaluate those
who have struggled with blood pressure controls due to
poor adherence to prescribed anti-hypertensive medica-
tions. The development of the MASES was based on the
results from open-ended interviews with 106 patients on
their experiences with anti-hypertensive medications.
Responses were divided into nine qualitative categories
with 43 questions to cover the barriers and facilitators to
medication adherence. MASES can also be used as a re-
search tool to assess the effectiveness of a behavioral in-
tervention program to enhance patients’ self-efficacy [9,
17, 18].
Several studies have investigated the medication com-
pliance among different cohorts of patients in Iran; how-
ever, none of these studies have assessed the medication
adherence using MASES, nor in hypertensive patients with
uncontrolled blood pressure. Thus, to assess the compli-
ance of anti-hypertensive medication in Iranian patients
with hypertension, we need a tool that is compatible with
the cultural background. Therefore, this study aimed to, (1)
translate the English version of Ogedegbe’s MASES into a
Persian version, and; (2) examine the reliability and va-
lidity in the patients with hypertension in Iran.
2 Material and Methods
2.1 Translation of the English Version
into a Persian Version
An agreement to translate the original MASES question-
naire was obtained by the authors. The first stage of cul-
tural adaptation was the translation of English
questionnaire into Persian language, which was performed
by two translators who are native English speakers and
fluent in Persian language (forward translation). One of the
translators was informed of the objectives and concepts of
the questionnaire, whereas the other one was blind. This
stage resulted in two translated versions. The differences
between the two versions were compared and resolved
between the two translators to yield the first final version
[19].
The English version of the MASES was again translated
by a native Iranian linguist, who is fluent in English and
was unaware of the purpose of the questionnaire. The
second translator is an Iranian cardiologist who was in-
formed of the objectives of the current study. Both versions
were assessed and consolidated between the researcher and
the translator into a second final version.
Both final versions were translated back into English by
another two native Persian-speaking translators who are
fluent in English. These two translators did not receive any
information on the concepts and purposes of the ques-
tionnaire. This procedure is the quality control of the ac-
curacy during the translation [19].
Then, the Persian questionnaire was completed by 20
hypertensive patients who were randomly selected from
those who were excluded from the main study, in order to
evaluate and validate the translated questionnaire. The data
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of the questionnaires were collected anonymously by the
authors for later evaluation. The difficulty level of the
Persian questionnaire were then evaluated by a panel of
experts in psychology, cardiology, and general practice
who are experienced in hypertension diagnosis and treat-
ment, as well as five hypertensive patients with different
education levels. Based on the assessment outcome, the
questionnaire was modified accordingly. In addition, lay
language has been used to replace the medical terminology.
Subsequently, the final version was again translated from
Persian into English by two bilingual translators indepen-
dently, who were unaware of the original English version
of the questionnaire. The discrepancies between the two
translated versions were again consolidated and the final
version of Persian MASES questionnaire was completed
for a formal assessment in hypertensive patients who met
the selection criteria.
2.2 The Evaluation of Validity and Reliability
The confidence of the questionnaire was evaluated using
internal consistency and re-tests reliability. Cronbach’s
alpha coefficient was used to assess the internal consis-
tency [20]. Interpretation of Item-total scale correlation
was used to assess the reliability of the questionnaire.
These coefficients were only acceptable if the value of the
Self-efficacy, the perception of one’s ability to complete a
task, a goal or a specific challenge (ICC) was greater than
0.3 and Cronbach’s alpha was equal to or greater than 0.7.
The exploratory Factor Analysis was used to assess the
factor structure of the questionnaire, and principal com-
ponent analysis was performed. Several tests were used to
assess the suitability of the respondent data before the
Factor Analysis, including Kaiser–Meyer–Olkin (KMO)
Measure of Sampling Adequacy, and Bartlett’s Test of
Sphericity. The KMO index is required when the case to
variation ratio is less than 1:5. The KMO index is ranged
from 0 to 1, with greater than 0.50 considered as suitable
for Factor Analysis. The Factor Analysis is only applicable
when the Bartlett’s Test of Sphericity is significant
(P\ 0.05). In order to determine the group validity,
MASES survey results from patients with well controlled
blood pressure were compared with those with uncon-
trolled hypertension. It was hypothesized that patients with
well controlled blood pressure would have higher self-ef-
ficacy scores than those with uncontrolled blood pressure.
Confirmatory Factor Analysis was performed using the
statistical software LISREL 8.80. The Model Fitness was
evaluated using Chi-square (v2), root mean square error of
approximation (RMSEA), Comparative Fit Index (CFI),
and Tucker–Lewis Index (TLI). Model modifications were
completed based on modification index and the results of
reliability analysis. The criteria used to determine a good
Model Fitness were a non-significant Chi-square results,
the ratio between Chi-square and its degrees of freedom
\2.0, the value of TLI and CFI C0.95, and the value of
RMSEA\0.06 [21, 22].
2.3 The Use of Persian Version of MASES
in Hypertensive Patients
This study was conducted in the health centers affiliated to
Qazvin University of Medical Sciences. This study was
approved by the Human Research Ethics Committee of
Qazvin University of Medical Sciences. All participants
have signed a consent form.
Based on the convenience sampling, 184 patients with
hypertension who were referred to the health service cen-
ters in Qazvin were recruited to participate in this study.
Inclusive criteria were: 18 years and above, proficient in
Persian language (understanding Persian language), lit-
eracy, using anti-hypertensive drugs for at least a year,
volunteered to participate in the study, and have regular
follow-up treatments for hypertension. The patients were
excluded if they had physical or cognitive disorders or
were unwilling to participate. The response rate was
95.83 %. Eight patients who were eligible for the study
were excluded due to unwillingness to participate. Statis-
tical tests showed that there was no significant difference
between the excluded and included patients in terms of
socio-demographic variables.
The MASES developed by Ogedegbe and colleagues [9]
has been used to assess the self-efficacy in the adherence to
anti-hypertensive medications in patients with high mor-
tality risk. The MASES is a patient-centered and self-ad-
ministered questionnaire that consists of 26 items. The
patient were asked to rate their confidence of taking anti-
hypertensive medications in different conditions using a
three-point scale (1 = unsure, 2 = somewhat sure, and
3 = very sure). This was performed by trained researchers
when the patients were attended in the waiting room before
their medical consultations. The total score of the 26 items
was then summed up. The score is positively correlated
with the level of self-efficacy, with higher score reflecting
higher self-efficacy. Original factor structure showed the
uni-dimensionality of the scale because the majority of
items in this structure were loaded on Factor 1. In addition
to the original MASES questions, several questions were
designed to measure the general characteristics (socio-de-
mographic) of the patient, including age, education, marital
status, job status, socioeconomic status, and the number of
medications used for controlling hypertension.
Blood pressure was measured twice with an interval of
10 min for each patient using an automated blood cuff by a
general practitioner who was blind to the participants
during the measurement. The average of the two
Persian Medication Adherence Self-Efficacy Scale
measurements was used [23]. Patients were resting in a
quiet room for 10 min before the first measurement and the
measurement was taken under the same condition [24].
P\ 0.05 was considered as significant for all the tests
(SPSS 17, Chicago, IL, USA).
3 Results
It only took 5 min to complete the questionnaire and the
questions are easy to understand by the patients. Cron-
bach’s alpha coefficient of the Persian version of the
MASES was[0.92, suggesting that this version can yield
consistent results over the time (25).
The general characteristics of the participants are shown
in Table 1. The age range of the participants was between
18 and 73 years old. Most participants in the study were
married and their education levels were below tertiary
degree. The majority of the patients were covered by the
health insurance. Two thirds of the patients were unem-
ployed, while most of the patients had fair or good eco-
nomic status. The duration of the disease varies between
the patients, as well as the number of the medication
(Table 1).
Table 2 shows the self-efficacy scores, item-to-total
correlation, kappa coefficients, and Cronbach’s alpha value
among 184 patents. Mean self-efficacy scores were ranged
from 1.72 to 2.28 with the standard deviations ranged from
0.51 to 0.81. For all items, the kappa values were ranged
from 0.28 to 1. The kappa value was less than 0.4 for two
items, while it was between 0.4–0.6 for 13 items. There are
eleven items with kappa values greater than 0.6. The
Cronbach’s alpha value was 0.91 for all 26 items. The
item-to-total correlation coefficients are between 0.248 and
0.685 for all items, which were all acceptable except for
Question 12 which reads, ‘‘When you are afraid that the
medications may affect your sexual performance’’.
Although the item-total correlation value for this question
was less than 0.3, it was not excluded from the current
study. This is because that its Chronbach’s alpha value was
0.917 and the removal of this question did not change the
internal consistency. In Addition, given that sexual dis-
ability is a barrier that is mentioned frequently by the pa-
tients, it was retained for its clinical importance, which has
also been included in the original MASES by Ogedegbe
and coworkers.
Table 3 shows the factor loadings of each question,
Eigen values, and the proportion of total variance against
each factor. The KMO Measure value of the data was
0.857, which suggests that there was sufficient and high
variability in the data to perform component analysis. The
results of Bartlett Test of Sphericity (approximate v2
(325) = 1780.5, P\ 0.001) as well as KMO confirmed the
factorability of the data. An Exploratory Principal Com-
ponents Factor Analysis performed on 26 items in the
MASES revealed a five-factor solution using the minimum
Eigen value criteria (\1). These five factors contributed to
about 67.8 % of the total variance (Table 3). Twenty out of
26 items were loaded in Factor 1. Two items were loaded
in Factors 2 and 3 and one item was loaded in Factors 4 and
5. Six items (6, 15, 17, 19, 23 and 24) had substantial
loadings on more than one factor (items with loadings
C0.4). Factor loading of all the items were acceptable.
The comparisons of Self-efficacy scores between the
patients with uncontrolled hypertension and those with
well-controlled blood pressure are shown in Table 4. The
former had significantly higher systolic (P\ 0.05) and
diastolic blood pressure (P\ 0.05) than the latter
(Table 4). The average efficacy score was higher in the
patients with controlled blood pressure than those with
uncontrolled hypertension (P\ 0.05), in 16 out of 26
questions (Table 4).
Table 1 General characteristics of the sample (n = 184)
Characteristics Total Percentage
Age (mean ± SD) 61.55 ± 12.83
Gender
Male 101 54.89
Female 83 45.11
Marital status
Married 119 64.66
Separated/divorced 17 9.24
Widow 44 23.92
Never married 4 2.18
Education level
Primary school 84 45.66
High school 85 46.18
University degree 15 8.16
Type of insurance
Social welfare 98 53.26
Remedial service 58 31.53
Self-paid 22 11.95
No insurance 6 3.26
Employment
Unemployed 126 68.47
Employed 58 31.53
Economic status
Low 37 20.11
Middle 83 45.11
Good 55 29.88
Excellent 9 4.90
Duration of hypertension (years) 6.00 ± 4.05
Number of medication 1.34 ± 0.85
Duration of treatment (years) 5.3 ± 3.64
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Hypertensive patients also showed lower medication
adherence self-efficacy compared with normotensive indi-
viduals and pre-hypertensive patients (Hypertensive-Nor-
mal systolic, ZMWU = -2.236, P = 0.025, Hypertensive-
Normal systolic, ZMWU = -3.025, P = 0.002, Hyperten-
sive-Normal diastolic, ZMWU = -2.716, P = 0.007,
Hypertensive-Normal diastolic, ZMWU = -3.147,
P = 0.002, (Table 5).
4 Discussion
This study modified the English version of MASES into
Persian language, according to the specificity of Iranian
culture. The validity and reliability were confirmed in
individuals with normal blood pressure and hypertensive
patients with/without well controlled blood pressure, where
patients with uncontrolled hypertension had significantly
lower self-efficacy to adhere to anti-hypertensive medica-
tions. The later clearly played a causal role in their un-
controlled hypertension.
The burden of chronic diseases, such as hypertension, is
incasing in developing countries [25]. Poor self-efficacy as
a contributing factor to increased rate of uncontrolled hy-
pertension shall receive more attention in these countries.
Despite the fact that this study was conducted in a devel-
oping country using a modified MASES on the adherence
to hypertension treatment, the results are consistent with
the studies using the original MASES in developed coun-
tries, where it has been suggested that non-adherence to
Table 2 Item analysis of the medication adherence self-efficacy scale
Self-efficacy
(mean ± SD)
Kappa
coefficients
Cronbach’s
alpha
ITC
How confident are you in taking your blood pressure medications?
1. When you are busy at home 1.92 ± 0.73 0.55 0.918 0.415
2. When you are at work/When you are busy with your daily
routines
1.87 ± 0.76 0.63 0.915 0.507
3. When there is no one to remind you 2.08 ± 0.71 0.48 0.915 0.506
4. When you worry about taking them for the rest of your life 1.92 ± 0.78 0.54 0.913 0.580
5. When they cause some side effects 1.78 ± 0.51 0.47 0.918 0.430
6. When they cost a lot of money 2.05 ± 0.75 0.46 0.914 0.535
7. When you come home late from work/when your work finishes
late
1.96 ± 0.66 0.72 0.914 0.569
8. When you do not have symptoms 1.82 ± 0.80 0.46 0.917 0.537
9. When you are with family members 2.01 ± 0.76 0.61 0.913 0.454
10. When you are in a public area 1.89 ± 0.8 0.42 0.916 0.551
11. When you are afraid of becoming dependent on them 1.82 ± 0.77 0.47 0.917 0.484
12. When you are afraid that they may affect your sexual
performance
1.81 ± 0.77 0.63 0.917 0.248
13. When the time to take them is between your meals 2.08 ± 0.68 0.65 0.912 0.475
14. When you feel that you don’t need them 1.73 ± 0.73 0.61 0.916 0.622
15. When you are traveling 1.78 ± 0.71 0.78 0.903 0.475
16. When you take them more than once a day 1.95 ± 0.72 1.00 0.916 0.370
17. If they sometimes make you feel tired 1.81 ± 0.68 0.28 0.915 0.485
18. If they sometimes makes you feel dizzy 1.81 ± 0.77 0.57 0.913 0.512
19. When you have other medications to take 2.04 ± 0.75 0.61 0.909 0.570
20. When you feel well 1.94 ± 0.83 0.55 0.917 0.665
21. If they make you want to urinate while away from the toilet 1.72 ± 0.75 0.65 0.915 0.449
How confident are you that you can carry out the following tasks?
22. Get refills for your blood pressure medications before they run
out
2.28 ± 0.75 0.84 0.915 0.517
23. Fill your prescriptions regardless of the cost 2.18 ± 0.79 0.45 0.915 0.510
24. Make your medications as part of your daily routine 2.12 ± 0.80 0.60 0.909 0.685
25. Always remember to take your blood pressure medications 2.05 ± 0.81 0.29 0.911 0.630
26. Take your blood pressure medications for the rest of your life 1.96 ± 0.83 0.47 0.916 0.472
ITC item-total scale correlation; SD standard deviation
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anti-hypertensive medication is a key issue in hypertension
management [4, 26]. Therefore, it is necessary to recognize
the poor self-efficacy to antihypertensive medication and
its cause factors, in order to impose behaviour changes in
such patients to improve their blood pressure control.
The concept of adherence used in this study is ‘‘a per-
son’s behaviours to take anti-hypertensive medications and
modify their diet and/or lifestyle correspond to the rec-
ommendations by the clinician, according to the guideline
of the World Health Organization [8]. Adherence to a
medication regimen requires a set of behaviors that include
obtaining the medication, timely administration of the
correct dose via recommended route, and keeping up with
the course of the treatment. The importance of adherence to
medication is well accepted. However, success in keeping
these behaviors can be hampered by many factors related to
aging. The loss of sensory function, disturbances of
memory and cognition, depression, and lifestyle changes
due to retirement can all disrupt the routine to maintain
regular medication [27–29]. The cessation of medication
can lead to symptom deterioration, increased chance of
hospitalizations, and increased morbidity and mortality
[30, 31].
As the adherence to anti-hypertensive therapy shall be
considered as a precaution of cardiovascular morbidity and
mortality, self-efficacy becomes an important factor to
assess medication adherence behaviour. However, the as-
sociation between self-efficacy and adherence to anti-hy-
pertensive therapy has not been well-characterised in Iran.
The current study using a Persian version of the MASE
among Iranian patients with hypertension showed that self-
efficacy is a strong determinant of medication adherence in
hypertensive patients, which is also closely related to their
blood pressure control.
Table 3 Principal component analysis of the MASES
Item Factors and loading
1 2 3 4 5
1. When you are busy at home 0.673
2. When you are at work/When you are busy with daily routines 0.677
4. When you worry about taking them for the rest of your life 0.721
5. When they cause some side effects 0.703
6. When they cost a lot of money 0.702 0.493
7. When you come home late from work/when your daily works finish late 0.741
8. When you do not have symptoms 0.740
11. When you are afraid of being dependent on them 0.735
12. When you are afraid that they may affect your sexual performance 0.775
13. When the time to take them is between your meals 0.761
14. When you feel you do not need them 0.691
15. When you are traveling 0.669 0.533
16. When you take them more than once a day 0.577
19. When you have other medications to take 0.568 0.466
20. When you feel well 0.577
21. If they make you want to urinate while away from the toilet 0.677
23. Fill your prescriptions regardless of the cost 0.718 0.561
24. Make your blood pressure medications as part of your daily routine 0.729 0.603
25. Always remember to take your blood pressure medications 0.742
26. Take your blood pressure medications for the rest of your life 0.773
9. When you are with family members 0.725
10. When you are in a public area 0.633
17. If they sometimes make you feel tired 0.619 0.750
18. If they sometimes make you feel dizzy 0.730
22. Get refills for your blood pressure medications before they run out 0.759
3. When there is no one to remind you 0.655
Eigen value 11.12 1.84 1.70 1.56 1.32
% explained variance 42.76 7.09 6.55 6.00 5.41
Cumulative % explained variance 42.76 49.85 56.40 62.40 67.81
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The self-efficacy, as stated by Bandura, is a self-belief of
the ability to perform some difficult tasks, relevant to this
study: taking complicated treatment regimens [32]. This
can be evaluated by the questions on patient’s attitude such
as ‘‘I can do it’’, or in hypertensive patients ‘‘I can take my
anti-hypertensive medication consistently’’. The latter
statement has been evaluated in this study using the Persian
MASES. Several studies have suggested the beneficial ef-
fects on health outcomes by implementing self-efficacy to
continue treatment programs [33, 34]. However, most of
these studies were on life-threatening infectious diseases,
such as HIV infection and chronic viral hepatitis [35–39].
In addition, in previous studies, self-efficacy has been
correlated with practicing self-care for the other chronic
Table 4 The MASES scores
between patients with
uncontrolled hypertension and
those with well-controlled blood
pressure
Items Hypertensive patients
Uncontrolled Controlled
1. When you busy at home 2.54 ± 0.64 2.75 ± 0.61
2. When you are at work/When you are busy with daily routines 2.11 ± 0.55 2.31 ± 0.82
3. When there is no one to remind you 2.83 ± 0.81 3.00 ± 0.00
4. When you worry about taking them for the rest of your life 2.66 ± 0.46 2.87 ± 0.58
5. When they cause some side effects 2.43 ± 0.49 2.79 ± 0.71
6. When they cost a lot of money 2.37 ± 0.87 2.54 ± 0.81
7. When you come home late from work/when your work finishes late 2.23 ± 0.87 2.21 ± 0.55
8. When you do not have symptoms 2.36 ± 0.78 2.77 ± 0.63
9. When you are with family members 2.75 ± 0.60 2.75 ± 0.90
10. When you are in a public area 2.42 ± 0.57 2.80 ± 0.54
11. When you are afraid of becoming dependent on them 2.77 ± 0.90 3.00 ± 0.00
12. When you are afraid they may affect your sexual performance 2.39 ± 0.82 2.21 ± 0.93
13. When the time to take them is between your meals 2.55 ± 0.64 2.76 ± 0.62
14. When you feel you do not need them 2.63 ± 0.63 2.82 ± 0.92
15. When you are traveling 2.41 ± 0.84 2.62 ± 0.76
16. When you take them more than once a day 2.52 ± 0.67 2.54 ± 0.70
17. If they sometimes make you tired 2.21 ± 0.99 2.38 ± 0.00
18. If they sometimes makes you feel dizzy 1.98 ± 0.53 1.83 ± 0.78
19. When you have other medications to take 2.51 ± 0.80 2.50 ± 0.63
20. When you feel well 2.43 ± 0.76 2.64 ± 0.73
21. If they make you want to urinate while away from the toilet 2.33 ± 0.60 2.12 ± 0.95
22. Get refills for your blood pressure medications before they run out 2.60 ± 0.49 2.44 ± 0.84
23. Fill your prescriptions regardless of the cost 2.46 ± 0.54 2.63 ± 0.66
24. Make your blood pressure medications as part of your daily routine 2.81 ± 0.73 2.76 ± 0.62
25. Always remember to take your blood pressure medications 2.50 ± 0.78 2.42 ± 0.95
26. Take your blood pressure medications for the rest of your life 2.71 ± 0.81 2.67 ± 0.66
Table 5 Patients’ self-efficacy
score for medication adherence
related to blood pressure
MASES-T
N Total score Average score of each item Test result
Systolic blood pressure
Normal (\120 mmHg) 51 68.4 ± 8.2 2.62 H value 10.280
Pre-hypertension (120–139 mmHg) 43 64.9 ± 7.1 2.57 P = 0.006
Hypertension (C140 mmHg) 90 62.2 ± 7.5 2.50
Diastolic blood pressure
Normal (\80 mmHg) 98 67.5 ± 9.2 2.59 H value 7.125
Pre-hypertension (80–89 mmHg) 65 64.8 ± 8.6 2.53 P = 0.028
Hypertension (C90 mmHg) 21 60.3 ± 8.4 2.47
H statistic (Kruskal Wallis variance analysis)
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conditions [40, 41]. This study demonstrated the significant
role of self-efficacy in treatment adherence among hyper-
tensive patients, with similar finding as the previous studies
[18, 42].
The findings of our study obtained from the Principal
Component Analysis suggested a structure of one-single
factor of the questionnaire. Although a 5-factor structure
was yielded, the Factor 1 is the dominant one, and the other
four factors could also be easily loaded onto factor 1. Thus
the uni-dimensionality of the Persian MASE is consistent
with the previous studies using the English MASES [9, 17,
18]. Ideally, at least 100–200 patients are required for the
Factor Analysis [43]. In our study, 189 patients par-
ticipated, which makes the analysis result acceptable to
validate the MASES. This was further confirmed by the
comparison between the patients with controlled and un-
controlled blood pressure. In this study, high value of
Cronbach’s alpha test was recognized and thus the item
redundancy was assessed. Although, several items were
closely correlated to each other, there was no redundancy
in the other items. This is because that each item refers to
different situation, all of which are essential to evaluate the
attitude towards self-efficacy and practice. The high in-
ternal consistency in this study suggests the reliability of
the questionnaire. Many currently available scales from the
other language focus on patient’s self-esteem or self-report
on the empowerment to take prescribed medication re-
gardless of patient’s concerns [37, 44]. Therefore, the
Persian MASES may offer a more holistic approach to
determine the self-efficacy in medication adherence than
the other measures due to the recognition of the patient’s
perception towards medications.
Moreover, based on the present and previous studies,
this MASES can distinguish the self-efficacy between hy-
pertensive patients with controlled and uncontrolled blood
pressure. Therefore, it can be used as a tool for the clin-
icians to monitor their patients’ confidence of using anti-
hypertensive medications. If the patients know little about
their health situation and the benefit of the medications,
they are less likely to comply to their medications [45].
Therefore, MASES can be a good tool to assess the ef-
fectiveness of the interventions to reinforce medical
knowledge in the patients, in order to increase the self-
efficacy of the patients to medication adherence [17]. In
our study, the patients with uncontrolled hypertension had
significantly lower self-efficacy than those with well con-
trolled blood pressure, which is similar to a previous study
in patients with hypertensive histories for more than one
year, but not newly diagnosed patients [46]. It has been
suggested that long duration of the disease could contribute
to a high level of self-efficacy.
There are still some limitations in this study. Firstly,
Convenience Sampling was used which may affect the
generality of the results. Further research is needed to use
random sampling in a larger scale including participants
from multiple health centers in Iran. Secondly, our study
relied on self-reporting, where certain biases of the patients
may affect the final results [47]. Therefore, alternative
options, such as electronic monitors or more objective re-
ports from the carers, are needed to achieve more accurate
information on medication adherence. Finally, the MASES
only questioned the current beliefs on medication adher-
ence, where it does not reflect the medical adherence in the
past, which may also affect the overall blood pressure
control.
5 Conclusion
The Persian MASES is useful to improve the evaluation of
confidence in medication adherence among patients with
hypertension. Thus, it can be used as a practical tool to
assess the self-efficacy among Iranian patients with hy-
pertension in medical practice, clinical studies, or clinical
trials.
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